МЕТОТРЕКСАТ И РИСК СЕРДЕЧНО-СОСУДИСТЫХ ОСЛОЖНЕНИЙ ПРИ РЕВМАТОИДНОМ АРТРИТЕ

1. <div><p>Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 720.</p><p>Meune C., Touze E., Trinqurte L., Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 2009; 48: 1309—13.</p><p>Meune C., Touze E., Trinquart L., Allanore Y. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and metaanalysis. Arch Cardiovasc Dis 2010; 103: 253—61.</p><p>Van Halm V.P., Peters M.J., Voskuyl A.E. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009; 68: 1395—400.</p><p>Nielen M.M., van Sijl A.M., Peters M.J. et al. Cardiovascular disease prevalence in a primary care cohort of individuals with inflammatory arthritis, diabetes, and osteoarthritis: a comparative cross-sectional study [abstract]. Arthr Rheum 2010; 62(Suppl 10): 2211.</p><p>Warrington K.J., Kent P.D., Frye R.L. et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthr Res Ther 2005; 7: 984—91.</p><p>Douglas K.M., Pace A.V., Treharne G.J. et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006; 65: 348—53.</p><p>Södergren A., Stegmayr B., Lundberg V. et al. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007; 66: 263-6.</p><p>Maradit-Kremers H., Crowson C.S., Nicola P.J. et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthr Rheum 2005; 52: 402-11.</p><p>Maradit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthr Rheum 2005; 52: 722-32.</p><p>Aubry M.C., Maradit-Kremers H., Reinalda M.S. et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34: 937-42.</p><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004; 440 с.</p><p>Насонов Е.Л., Попкова Т.В. Кардиоваскулярные проблемы ревматологии. Науч.-практич. ревматол. 2004; 4: 4-9.</p><p>Gazi I.F., Boumpas D.T., Mikhailidis D.P. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol 2007; 25: 102-11.</p><p>Попкова Т.В., Новикова Д.С., Насонов Е.Л. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. M.: ГЭОТАР-Медиа, 2010; 678-702.</p><p>Teir J., Koduri G., Meadows A. et al. Letter to the editor (other). An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. Rheumatology (Oxford) 2008; 47: 1252-4.</p><p>Sattar N., McCarey D.W., Capell H. et al. Explaining how «highgrade» systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.</p><p>Александрова Е.Н., Новиков А.А., Насонов Е.Л. Высокочувствительные методы определения С-реактивного белка (обзор литературы). Клин. лаб. диагн. 2004; 11: 16-8.</p><p>Van Halm V.P., Nielen M.M., Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184-8.</p><p>Holmqvist M.E., Wedren S., Jacobsson L.T. et al. Rapid increase in myocardial infarction risk following diagnosis of RA amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268: 578-85.</p><p>Goodson N.J., Symmons D.P., Scott D.G. et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthr Rheum 2005; 52: 2293-9.</p><p>Poole C.D., Conway P., Currie C.J. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-medi-ated inflammatory disease managed in UK general practice. Rheumatology (Oxford) 2009; 48: 78-82.</p><p>Jacobsson L.T., Turesson C., Hanson R.L. et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthr Rheum 2001; 44: 1170-6.</p><p>Wallberg-Jonsson S., Johansson H., Ohman M.L. et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71.</p><p>Rho Y.H., Chung C.P., Oeser A. et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthr Rheum 2009; 61: 1580-5.</p><p>Goodson N.J., Wiles N.J., Lunt M. et al. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthr Rheum 2002; 46: 2010-9.</p><p>Lopez-Longo F.J., Oliver-Minarro D., de la Torre I. et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum 2009; 61: 419-24.</p><p>Solomon D.H., Kremer J., Curtis J.R. et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69(11): 1920-5.</p><p>Karlson E.W., Chibnik L.B., Tworoger S.S. et. al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthr Rheum 2009; 60(3): 641-52.</p><p>Gerli R., Bartoloni Bocci E., Sherer Y. et al. Association of anticyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 724-5.</p><p>Ross R. Atherosclerosis — an inflammatory disease. Am Heart J 1999; 138: 419-20.</p><p>Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 2003; 91: 3-6.</p><p>Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48: 11-22.</p><p>Sattar N., Mclnnes I.B. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol 2005; 17: 286-92.</p><p>Tedgui A., Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res 2001; 11: 877-87.</p><p>Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-45.</p><p>Full L.E., Ruisanchez C., Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthr Res Ther 2009; 11: 217.</p><p>Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008; 121(Suppl 1): 21—31.</p><p>Pasceri V., Yeh E.T. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-6.</p><p>Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86(2): 515—81.</p><p>Pincus T., Yazici Y., Sokka T. et al. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21(5 Suppl 31): S179-S185.</p><p>Gutierrez-Urena S., Espinoza L.R. Methotrexate: the agent of choice for chronic inflammatory disorders. A perspective ten years later. Clin Exp Rheumatol 1995; 13(3): 281-4.</p><p>Rau R., Herborn G. Benefit and risk of methotrexate treatment in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22(5 Suppl 35): S83-S94.</p><p>Насонов Е.Л. Метотрексат: перспективы применения в ревматологии. М.: Филоматис, 2005; 200.</p><p>Braun J. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthr Rheum 2008; 58(1): 73—81.</p><p>Chang D.M., Weinblatt M.E., Schur P.H. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 1992; 19(11): 1678-82.</p><p>Seitz M., Loetscher P., Dewald B. et al. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995; 34(7): 602-9.</p><p>Seitz M., Loetscher P., Dewald B. et al. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8-markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 1996; 23(9): 1512-6.</p><p>Miossec P., Briolay J., Dechanet J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthr Rheum 1992; 35(8): 874—83.</p><p>Seitz M., Zwicker M., Wider B. Enhanced in vitro induced production of interleukin 10 by peripheral blood mononuclear cells in rheumatoid arthritis is associated with clinical response to methotrexate treatment. J Rheumatol 2001; 28(3): 496—501.</p><p>Segal R., Yaron M., Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthr Rheum 1990; 20(3): 190—200.</p><p>Cronstein B., Reiss A. Immunologic reactants in the pathogenesis of atherosclerosis in rheumatic diseases. Arthr Rheum 2003; 5(Suppl 3): 44.</p><p>Morita Y., Fukazawa T., Hirashima M. et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. Scand J Rheumatol 2006; 35(4): 268—72.</p><p>Kalda A., Yu L., Oztas E., Chen J. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. J Neurol Sci 2006; 248(1—2): 9—15.</p><p>Cohen M.V., Downey J.M. Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008; 103(3): 203—15.</p><p>Del Rincon I.D., Williams K., Stern M.P. et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthr Rheum 2001; 44: 2737—45.</p><p>Dessein P.H., Joffe B.I., Veller M.G. et al. Traditional and non-traditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435—42.</p><p>Van Halm V.P., Nielen M.M., Nurmohamed M.T. et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184—8.</p><p>Nielen M.J., van Halm V.P., Numohamed M.T. et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum 2003; 48: 344—50.</p><p>Navab M., Berliner J.A., Subbanagounder G. et al. HDL and inflammatory response induced by LDL-derived oxidized phospholipids. Arteriol Thromb Vasc Biol 2001; 21: 481—8.</p><p>McMahon M., Grossman J., FitzGerald J. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthr Rheum 2006; 54(8): 2541—9.</p><p>Sattar N., Choi E. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460—9.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль нарушений в системе транспорта холестерина крови в развитии атеросклероза при ревматоидном артрите. Науч.-практич. ревматол. 2007; 5: 4 —10.</p><p>Choi E., Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460—9.</p><p>Navab M., Hama S.Y., Anantharamaiah G.M. et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495—508.</p><p>Navab M., Hama-Levy S., van Lenten B.J. et al. Mildlyoxidised LDL induces an increased apolipoproteinparaoxonase ratio. J Clin Invest 1997; 99: 2005—19.</p><p>Mackness M.I., Arrol S., Durrinton P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152—4.</p><p>Watson A.D., Navab M., Hama S.Y. et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774—182.</p><p>Gomaraschi M., Basilico N., Sisto F. et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to proinflammatory stimuli. Biochim Biophys Acta 2005; 1736: 136—43.</p><p>Coomes E., Chan E.S., Reiss A.B. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol 2011; article ID: 503028.</p><p>Chen D.Y., Chih H.M., Lan J.L. et al. Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment. BMC Med 2011; 9: 4.</p><p>Reiss A.B., Carsons S.E., Anwar K. et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthr Rheum 2008; 58(12): 3675—83.</p><p>Joost H.G., Weber T.M., Cushman S.W. et al. Insulin-stimulated glucose transport in rat adipose cells. Modulation of transporter intrinsic activity by isoproterenol and adenosine. J Biol Chem 1986; 261(22): 10033—6.</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359(9313): 1173—7.</p><p>Mikuls T.R., Fay B.T., Michaud K. et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011; 50(1): 101—9.</p><p>Wasco M.C.M., Dasgupta A., Hubert H. et al. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthr Rheum 2012; 10: art.37723.</p><p>Boyer J.F., Cantagrel A., Constantin A. Impact of traditional therapies and biologics on cardiovasculardiseases in rheumatoid arthritis. Curr Vasc Pharmacol 2008; 6(3): 218—27.</p><p>Westlake S.L., Colebatch A.N., Baird J. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010; 49(2): 295—307.</p><p>Van Halm V.P., Nurmohamed M.T., Twisk J.W. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthr Res Ther 2006; 8(5): R151.</p><p>Hochberg M.C., Johnston S.S., John A.K. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24(2): 469—80.</p><p>Naranjo A., Sokka T., Descalzo M.A. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthr Res Ther 2008; 10(2): R30.</p><p>Goodson N.J. The mortality association with DMARD usein early inflammatory polyarthritis [abstract]. Rheumatology 2008; 47: ii49.</p><p>Greenberg J.D., Kremer J.M., Curtis J.R. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576—82.</p><p>Radovits B.J., Popa-Diaconu D.A., Popa C. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009; 68(8): 1271—6.</p><p>Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthr Rheum 2006; 55(4): 531—6.</p><p>Edwards C.J. Myocardial infarction in rheumatoid arthritis. The effects of DMARDs and prednisolone [abstract]. Arthr Rheum 2008; 56: 668.</p><p>Prodanovich S., Ma F., Taylor J.R., Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52(2): 262—7.</p><p>Endean A. The risk of stroke in patients with rheumatoid arthritis compared to the general population [abstract]. Arthr Rheum 2007; 56: S293.</p><p>Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44(5): 677—80.</p><p>Myasoedova E., Crowson C.S., Nicola P.J. еt al. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011; 38(8): 1601—6.</p><p>Micha R., Imamura F., Wyler von Ballmoos M. et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108(9): 1362—70.</p><p>Wallberg-Jonsson S., Ohman M., Rantapä ä-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol 2004; 33(6): 373—9.</p><p>Kumeda Y., Inaba M., Goto H. et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthr Rheum 2002; 46(6): 1489—97.</p><p>Landewe R.B., van den Borne B.E., Breedveld F.C. et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet 2000; 355: 1616—7.</p><p>Georgiadis A.N., Papavasiliou E.C., Lourida E.S. et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment — a prospective, controlled study. Arthr Res Ther 2006; 8(3): R82.</p><p>Park Y.B., Choi H.K., Kim M.Y. et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113(3): 188—93.</p><p>Dessein P.H., Joffe B.I., Stanwix A.E. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthr Res 2002; 4(6): R12.</p><p>Toms T.E., Panoulas V.F., John H. et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 — more than just an anti-inflammatory effect? A cross sectional study. Arthr Res Ther 2009; 11(4): R110.</p><p>Raterman H.G., Voskuyl A.E., Dijkmans B.A., Nurmohamed M.T. Use of methotrexate therapy is not associated with decreased prevalence of metabolic syndrome. Arthr Res Ther 2009; 11(5): 413.</p><p>Panoulas V.F., Douglas K.M., Milionis H.J. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46(9): 1477—82.</p><p>De Bree A., Verschuren W.M., Kromhout D. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002; 54(4): 599—618.</p><p>Van Ede A.E., Laan R.F., Blom H.J. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41(6): 658—65.</p><p>Morgan S.L., Baggott J.E., Refsum H., Ueland P.M. Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate. Clin Pharmacol Ther 1991; 50(5 Pt 1): 547—56.</p><p>Morgan S.L., Baggott J.E., Lee J.Y., Alarcon G.S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol 1998; 25(3): 441—6.</p><p>Hernanz A., Plaza A., Martin-Mola E., de Miguel E. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999; 32(1): 65—70.</p><p>Roubenoff R., Dellaripa P., Nadeau M.R. et al. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthr Rheum 1997; 40(4): 718—22.</p><p>Cronstein B.N. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005; 57(2): 163—72.</p></div><br />